NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.

MLA

Young, Matthew, et al. “NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.” Clinical Genitourinary Cancer, vol. 22, no. 3, June 2024, p. 102072. EBSCOhost, https://doi.org/10.1016/j.clgc.2024.102072.

APA

Young, M., Tapia, J. C., Szabados, B., Jovaisaite, A., Jackson-Spence, F., Nally, E., & Powles, T. (2024). NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer, 22(3), 102072. https://doi.org/10.1016/j.clgc.2024.102072

Chicago

Young, Matthew, Jose C Tapia, Bernadett Szabados, Agne Jovaisaite, Francesca Jackson-Spence, Elizabeth Nally, and Thomas Powles. 2024. “NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.” Clinical Genitourinary Cancer 22 (3): 102072. doi:10.1016/j.clgc.2024.102072.